Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07184450 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases

Name: Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases — clinical trial record (NCT07184450)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorChongqing Precision Biotech Co., Ltd

Started2025-09-01

View on ClinicalTrials.gov ↗

Record status

This record was last updated September 19, 2025 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.

Chongqing Precision Biotech Co., Ltd

36 trials monitored

See 1 trial at risk

Scleroderma

302 trials monitored

See 9 trials at risk

This is an investigator-initiated trial to evaluate the efficacy and safety of BCMA/CD70-targeted CAR-T in the treatment of refractory pediatric rheumatic diseases.

Trial Details

NCT Number	NCT07184450
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis, Systemic Sclerosis (SSc), Primary Sjogren's Syndrome
Enrollment	11 participants
Start Date	2025-09-01
Primary Completion	2026-03-30 (estimated)
Study Completion	2028-09-30 (estimated)
Updated on ClinicalTrials.gov	2025-09-19